In a new JAMA Dermatology study, scientists at King's College London found that changes in two parts of the genome work ...

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

The risk for alopecia areata is increased among patients with lower serum levels of vitamin D and zinc, but no relationship was observed with copper.

Comorbid chronic inflammatory diseases influence the prognosis of alopecia areata, according to study findings.

Everyone’s alopecia areata is different. Even though everyone who has it experiences hair loss, it may have many variations, including where, when, and how often you lose your hair. Alopecia ...

If you haven’t found the right treatment for your alopecia areata yet, it may be right around the corner. There’s no cure for alopecia areata, but even with this condition, your hair follicles ...

DelveInsight's Alopecia Areata Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. LAS VEGAS, NV, UNITED STATES, January 15, 2025 /EINPresswire ...

HCW Biologics Inc. has received clearance of its IND application from the FDA to initiate a first-in-human phase I trial to ...